Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

IND filed for new insomnia drug candidate from Neurogen and Pfizer

Sep. 17, 1998

GW-273227, a sodium channel blocker for the treatment of pain

Sep. 17, 1998

Glaxo Wellcome studies lamotrigine analogues in the search for new anticonvulsants

Sep. 17, 1998

Astra Arcus develops first full, selective alpha7 nAChR agonist

Sep. 17, 1998

Selective 5-HT2C antagonist selected for development at Organon

Sep. 17, 1998

European marketing application for Myotrophin withdrawn

Sep. 16, 1998

Algos releases phase III clinical trial results for MorphiDex

Sep. 16, 1998

Merck KGaA discovers potent dual 5-HT1A antagonist and 5-HT reuptake inhibitor

Sep. 16, 1998

S-23751: new 5-HT1A/5-HT7 receptor ligand with anxiolytic activity

Sep. 16, 1998

Potent and selective 5-HT1B/1D antagonists designed by Merck KGaA

Sep. 16, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...